Identifying targets of autoantibodies

Patients with the autoimmune disease systemic lupus erythematosus (SLE) produce autoantibodies that target can cause damage to multiple organ systems. The host factors that are targeted by autoantibodies produced by SLE patients are not fully understood.

In this issue of the Journal of Clinical Investigation, Jordan Price and colleagues at Stanford University developed a microarray to identify cytokines, chemokines, and other circulating proteins as potential targets of the autoantibodies produced by SLE patients. The authors identified several autoantibody targets, and determined that SLE patients with high levels of directed against the B cell activating factor (BAFF) had more severe SLE-associated symptoms.

In an accompanying commentary, Maureen Su of the University of North Carolina and Stephanie Sarantopoulos of Duke University discuss how identification of autoantibody targets produced by patients with will be informative for diagnosis and therapeutic strategy development.


Explore further

Protein implicated in lupus promotes disease progression by distinct mechanisms in different immune cells

More information: Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus, J Clin Invest. DOI: 10.1172/JCI70231
BAFF-ling autoantibodies, J Clin Invest. 2013;123(12):5006–5008. DOI: 10.1172/JCI73166
Citation: Identifying targets of autoantibodies (2013, November 25) retrieved 23 August 2019 from https://medicalxpress.com/news/2013-11-autoantibodies.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more